HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Humacyte, Inc. Investors With Substantial Losses Have Opportunity To Lead Class Action Lawsuit
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Humacyte, Inc. Investors With Substantial Losses Have Opportunity To Lead Class Action Lawsuit . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 NEW YORK, Nov. 29, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that ...
América - MenaFN
(MENAFN- PR Newswire)

NEW YORK, Nov. 29, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA ) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg/HUMA.

Case Details

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg/HUMA. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660 . If you suffered a loss in Humacyte you have until January 04, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660

| [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108940369/HUMA-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-That-Humacyte-Inc-Investors-With-Substantial-Losses-Have-Opportunity-To-Lead-Class-Action-Lawsuit
2024-11-29
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 NEW YORK, Nov. 29, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that ...
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Humacyte, Inc. Investors With Substantial Losses Have Opportunity To Lead Class Action Lawsuit